Open-label treatment with citalopram in patients with irritable bowel syndrome: A pilot study

Abstract

Background: This open-label pilot study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram improves symptoms of irritable bowel syndrome (IBS), a functional gastrointestinal disorder with frequent psychiatric comorbidity. Method: Fifteen patients meeting Rome I criteria for IBS were administered open-label citalopram (20-40 mg/day) for 12 weeks. The study was conducted from October 2000 to August 2001. Results: Twelve (80%) of the 15 subjects reported a ≥ 50% decrease in the presence of abdominal pain, 10 (67%) reported a ≥ 50% reduction in the severity of the symptom, and 12 (80%) reported a ≥ 50% reduction in the frequency of the symptom. Approximately one half of the patients met criteria for remission (≥ 70% improvement) of abdominal pain. Conclusion: Results of this pilot study suggest that large controlled trials are needed to further evaluate the efficacy of SSRIs such as citalopram for the treatment of IBS. © Copyright 2005 Physicians Postgraduate Press, Inc.